MEDIGENE
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer.
MEDIGENE
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1994-01-01
Address:
Martinsried, Bayern, Germany
Country:
Germany
Website Url:
http://www.medigene.com
Total Employee:
11+
Status:
Active
Contact:
+49-89-20 00 33 - 29 20
Total Funding:
26 M EUR
Technology used in webpage:
SSL By Default Font Awesome Amazon PHP 7 CloudFront Amazon SSL Apple Whitelist Amazon Ireland Region Amazon Elastic Load Balancing Amazon Elastic Load Balancing Sticky Session
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Alkermes
Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Correvio
Correvio specializes in critical care with a deep understanding of interventional cardiology.
CytunePharma
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.
Exscientia
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Fresenius Kabi AG
Fresenius Kabi AG, a health care company, specializes in lifesaving medicines and technologies.
Oxford Vacmedix
Develop therapeutic agents for the treatment of cancer .
Preclin Biosystems
Preclin Biosystems offers a comprehensive in vivo preclinical testing platform.
Teva Laboratoires
Teva Laboratoires is a laboratory that specializes in the production of generic drugs and specialty neurology.
Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for infectious diseases and cancer.
Current Advisors List
Board_member
Current Employees Featured
James Noble Non Executive Director @ MediGene
Non Executive Director
Gerrit Brandt Director Accounting and Controlling @ MediGene
Director Accounting and Controlling
Dolores Schendel Chief Scientific Officer and Managing Director @ MediGene
Chief Scientific Officer and Managing Director
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2000-11-09 | Neurovir Therapeutics | Neurovir Therapeutics acquired by MediGene | N/A |
Investors List
BioNTech
BioNTech investment in Post-IPO Equity - MediGene
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-07-27 | leon nanodrugs | MediGene investment in Series A - leon nanodrugs | 18.5 M EUR |
Official Site Inspections
http://www.medigene.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.81 K
- Host name: 112.84.207.35.bc.googleusercontent.com
- IP address: 35.207.84.112
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "MediGene"
Landingpage - Medigene AG
Medigene is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates …See details»
Company - Medigene AG
Medigene’s corporate vision is to fully leverage our End-to-End platform designing and developing 3S TCR-guided immuno-therapies across multiple drug modalities and multiple indications.See details»
Partners - Medigene AG
In order to change the paradigm of cancer treatment, Medigene seeks partnerships with other leaders in the field to exploit the full potential of our immunotherapy technology platforms. Therefore, we are already collaborating …See details»
MediGene - Wikipedia
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers. The first product candidates are in clinical development. See details»
Medigene AG - LinkedIn
Medigene AG | 7,632 followers on LinkedIn. Living Immunotherapies | Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell …See details»
MediGene - Crunchbase Company Profile & Funding
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer. A comprehensive platform for developing T cell receptor (TCR)-guided therapies, including TCR …See details»
Home - Medigen
Medigen, Inc. is a biomedical company developing safe and effective vaccines against emerging diseases. Our goal is to protect human life with life-long immunity. Focus on vaccine safety …See details»
Overview - Medigene AG
Nov 12, 2024 · Yes, I would like to receive information from Medigene Consent to privacy When you submit your data, it will be processed by Medigene AG, Lochhamer Str. 11, 82152 Planegg/Martinsried for the purpose of sending you …See details»
Medigene AG Company Profile | Planegg, Bayern, Germany
Find company research, competitor information, contact details & financial data for Medigene AG of Planegg, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
Medigene AG (MDGEF) Company Profile & Overview - Stock Analysis
Nov 13, 2024 · Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end …See details»
Medigene AG - LinkedIn
Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer.See details»
Medigene Announces Strategy and Corporate Update - Yahoo …
Nov 15, 2022 · We are focused on delivering best-in-class TCR-T therapies to patients suffering from difficult to treat tumors and have accelerated and prioritized our research activities.See details»
Medigene Reports Financial Results and Corporate Update for
Oct 26, 2023 · Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell …See details»
Medigene AG Expands its End-to-End Platform by Submitting …
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and …See details»
Medigene Announces Strategy and Corporate Update
Nov 16, 2022 · Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor …See details»
Medigene Company Profile - Office Locations, Competitors ... - Craft
Oct 25, 2024 · Medigene is a biotechnology company. It develops innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and …See details»
Medigene Announces Strategy and Corporate Update
Nov 15, 2022 · Medigene AG (FSE: MDG1) is a late pre-clinical stage immuno-oncology company, focusing on discovering and developing differentiated, breakthrough cellular …See details»
BioNTech and Medigene Announce Global Collaboration to …
Feb 21, 2022 · Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. …See details»
Pipeline - Medigene AG
Medigene’s proprietary End-to-End Platform for identifying, selecting and engineering best-in-class TCRs is protected by exclusively in-licensed and proprietary patents in Europe, North …See details»
MEDIGENE
Medigene is a India's Leading Online Platform for Doctors with Accredited Medical CMEs, Latest Medical News, Conference Highlights, CME Credit Points, Patient Education Programs, …See details»